Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | FRK | P42685 | 2/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601390 | 0.83 | MAPK14 (0.43) | MAPK14MAPK11MAPK13MAPK12MAPK9 | |
| SCHEMBL8418263 | 0.71 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12MAPK9 | |
| SCHEMBL1639908 | 0.71 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12MAPK9 | |
| SCHEMBL8477798 | 0.71 | MAPK14 (0.78) | MAPK14MAPK11MAPK13MAPK12MAPK9 | |
| SCHEMBL1640808 | 0.69 | CSNK1D (0.45) | MAPK14MAPK9MAP4K4EGFRFRK | |
| SCHEMBL1640801 | 0.67 | GPR119 (0.49) | MAPK14CSNK1D | |
| SCHEMBL8420006 | 0.67 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12EGFR | |
| SCHEMBL1639208 | 0.65 | CSNK1D (0.57) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL1640317 | 0.65 | MAPK14 (0.75) | MAPK14MAPK11MAPK13MAPK12MAPK9 | |
| SCHEMBL12221555 | 0.65 | MAPK14 (0.74) | MAPK14MAPK11MAPK13MAPK12MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005032551-A1 | TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005030091-A2 | STENTS AND INTRA-LUMINAL PROSTHESES CONTAINING MAP KINASE INHIBITORS | SCIOS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040162289-A1 | Methods of promoting osteogenesis | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2004-08-19 | — | — | US | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | MAPK14 36/4885MAPK11 39/4885MAPK13 34/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK11 37/4885MAPK13 15/4885 |
| US-20040162289-A1 | Methods of promoting osteogenesis | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK11 37/4885MAPK13 15/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK11 50/4885MAPK13 39/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK11 50/4885MAPK13 39/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | MAPK14 53/4885MAPK11 45/4885MAPK13 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.